| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/08/2006 | US7087636 A 4,7-methano-1,2-benzisothiazol-3-one-1,1-dioxide derivatives, for treating cancer, immune modulation |
| 08/08/2006 | US7087634 Cyclic AMP-specific phosphodiesterase inhibitors |
| 08/08/2006 | US7087627 Synergistic mixture of vasculation damaging agent such as tubulin binding agent and inhibitor of forming of nitric oxide; antitumor agents; anticancer agents |
| 08/08/2006 | US7087626 TGF-beta signal transduction inhibitors |
| 08/08/2006 | US7087614 Pyrimidine inhibitors of phosphodiesterase (PDE) 7 |
| 08/08/2006 | US7087613 Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| 08/08/2006 | US7087608 Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 08/08/2006 | US7087603 Pyrazole compounds useful as protein kinase inhibitors |
| 08/08/2006 | US7087601 Psychological disorders; anxiolytic agents; antidepressants; analgesics ; schizophrenia |
| 08/08/2006 | US7087588 to gastrointestal systems, kidneys |
| 08/08/2006 | US7087584 Detection and modulation of IAPs and NAIP for the diagnosis and treatment of proliferative disease |
| 08/08/2006 | US7087581 Regeneration of sensitive cells with cell proliferative agents; cyclin-dependent kinase inhibitor; administering antibody |
| 08/08/2006 | US7087405 Anticancer agents; rheumatic diseases; genetic engineered plasmid |
| 08/08/2006 | US7087399 Purification; analyzing; drug screening; Alzheimer's diseases; central nervous system disorders |
| 08/08/2006 | US7087250 Therapeutic composition providing respiratory relief |
| 08/08/2006 | US7087237 Ocular solutions |
| 08/08/2006 | US7087236 Parenterally administering to a subject microparticles comprising at least one antigen entrapped or encapsulated in a biodegradable polymer, wherein biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers |
| 08/08/2006 | US7087225 Nucleotide sequences coding polypeptide for use in treatment, diagnosis and prevention of bone disorders |
| 08/08/2006 | US7087224 Method of treating anemia by administering IL-1ra |
| 08/08/2006 | US7087217 Condensation aerosol for delivery of a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone |
| 08/08/2006 | US7087216 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone |
| 08/08/2006 | US7087215 Methods of administering and enhancing absorption of pharmaceutical agents |
| 08/08/2006 | CA2394902C Effervescent histamine h2 antagonist composition |
| 08/08/2006 | CA2358938C Methods for assessing, improving, or maintaining urogenital health in postmenopausal women |
| 08/08/2006 | CA2356985C 5ht1 antagonists for antidepressant therapy |
| 08/08/2006 | CA2348016C Controlled release liquid delivery compositions with low initial drug burst |
| 08/03/2006 | WO2006080952A2 Improved modalities for the treatment of degenerative diseases of the retina |
| 08/03/2006 | WO2006080582A1 Agent for control of function of antigen-presenting cell |
| 08/03/2006 | WO2006080581A1 Agent for control of degranulation reaction and cytokine production |
| 08/03/2006 | WO2006080524A1 Medicinal composition for ameliorating or treating glucose intolerance, borderline diabetes, insulin resistance and hyperinsulinemia containing hypoglycemic agent |
| 08/03/2006 | WO2006080505A1 Hair growing tonic, hair growing tonic composition and method of hair growth and restoration |
| 08/03/2006 | WO2006080483A1 Novel dendritic cell membrane molecule and dna encoding the same |
| 08/03/2006 | WO2006080406A1 Tricyclic compounds |
| 08/03/2006 | WO2006080385A1 Method of screening therapeutic agent for irritable bowel syndrome |
| 08/03/2006 | WO2006080340A1 Concomitant use of hepatitis c virus-origin peptide with interferon |
| 08/03/2006 | WO2006080087A1 Method of screening antistress substance and antistress agent |
| 08/03/2006 | WO2006079853A1 Analgesic compositions |
| 08/03/2006 | WO2006079811A1 Reducing drug dependence or addiction |
| 08/03/2006 | WO2006079796A1 Treatment for mucositis |
| 08/03/2006 | WO2006079792A1 Methods of autophagy induction in mammalian cells |
| 08/03/2006 | WO2006079496A1 New pharmaceutical composition containing candesartan cilexetil as lipophilic crystalline substance |
| 08/03/2006 | WO2006079176A1 Molecules and chimeric molecules thereof |
| 08/03/2006 | WO2006062681A9 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 08/03/2006 | WO2006060507A3 Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| 08/03/2006 | WO2006033734A3 Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| 08/03/2006 | WO2005079849A3 Compounds for enhanced cancer therapy |
| 08/03/2006 | WO2005046659A3 Migraine treatments including isovaleramide compounds and serotonin agonists |
| 08/03/2006 | WO2005037225A3 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
| 08/03/2006 | WO2004058171A3 Antibodies against gpr64 and uses thereof |
| 08/03/2006 | WO2004007680A3 Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing an adenosine kinase |
| 08/03/2006 | WO2004001381A8 Novel raag10 cell surface target and a family of antibodies recognizing that target |
| 08/03/2006 | US20060173079 Compositions and methods for improving the condition of patients suffering from copd and other diseases |
| 08/03/2006 | US20060173076 Antibiotic/benzoyl peroxide dispenser |
| 08/03/2006 | US20060172997 Combinations of inhibitors of reverse transcriptase and inhibitors of virus-encoded DNA polymerase |
| 08/03/2006 | US20060172971 e.g. 2-[(2-bromo-4-fluoro-phenyl)-hydrazono]-propionic acid ethyl ester; protein tyrosine kinase inhibitor, but does not inhibit ATP binding to the protein tyrosine kinase; and as anticarcinogenic agent, psoriasis, atherosclerosis, or immune system activity |
| 08/03/2006 | US20060172970 Scleroderma; side effect reduction |
| 08/03/2006 | US20060172966 Immunostimulatory G, U-containing oligoribonucleotides |
| 08/03/2006 | US20060172960 cellular senescence and immortalization; administering a telemerase inhibitor; reduced loss of telomere length; antiproliferative agents |
| 08/03/2006 | US20060172955 Antibiotic/benzoyl peroxide dispenser |
| 08/03/2006 | US20060172950 Hepatitis C virus inhibitors |
| 08/03/2006 | US20060172949 administering a protein agonist for protease-activated receptor (PAR-2); side effects reduction; peptidase inhibitors (amistatins); drug delivery; biodrugs as antisecretory agents |
| 08/03/2006 | US20060172921 Method for identifying active anti-apoptosis compounds |
| 08/03/2006 | US20060172348 incubating a cell or tissue sample with a purified antibody or an antigen binding fragment that binds specifically to a portion of human NAIP protein, detecting binding of antibody to such cell or tissue sample |
| 08/03/2006 | US20060172288 methods of identifying susceptibility of cells to reovirus infection by measuring constitutive ras-MAP signaling; provides for reovirus treatment of mammals to treat proliferative disorders including breast tumors, a subset of tumors in which mutation of ras gene is not believed to play significant role |
| 08/03/2006 | US20060171974 Compounds, formulations, and methods for treating or preventing rosacea |
| 08/03/2006 | US20060171953 Tumour-specific animal proteins |
| 08/03/2006 | US20060171937 Method of treating chronic cardiac disease |
| 08/03/2006 | US20060171916 water insoluble polyallylamine copolymer (hydrochloride) crosslinked with epichlorohydrin crosslinking agent; decreasing serum level of phosphate by binding phosphate in gastrointestinal tract, without increasing absorption of any clinically undesirable material, as calcium or aluminum; hyperphosphatemia |
| 08/03/2006 | DE10394175T5 Zusammensetzung mit einem botanischen Extrakt mit Anti-Krebs- oder phytoöstrogener Aktivität, enthaltend Prenyflavonoide Composition with a botanical extract with anti-cancer activity or phytoöstrogener containing Prenyflavonoide |
| 08/03/2006 | CA2596537A1 Molecules and chimeric molecules thereof |
| 08/03/2006 | CA2596371A1 Agent for control degranulation reaction and cytokine production |
| 08/03/2006 | CA2596227A1 Improved modalities for the treatment of degenerative diseases of the retina |
| 08/03/2006 | CA2596057A1 Method of screening therapeutic agent for irritable bowel syndrome |
| 08/03/2006 | CA2595879A1 Analgesic compositions |
| 08/02/2006 | EP1686130A1 Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents |
| 08/02/2006 | EP1686113A1 Inhibitors of aspartyl protease |
| 08/02/2006 | EP1685849A1 Remedy for chronic pelvic pain syndrome |
| 08/02/2006 | EP1685847A1 Beta-amyloid-analogue-T-cell epitop vaccine |
| 08/02/2006 | EP1685842A2 Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| 08/02/2006 | EP1685839A1 Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist |
| 08/02/2006 | EP1685833A1 Remedy for diabetes |
| 08/02/2006 | EP1685832A1 Nerve regeneration promoters |
| 08/02/2006 | EP1685135A1 Tetrahydro-furo¬3,4-d|dioxole compounds and compositions and method for inhibiting platelet aggregation |
| 08/02/2006 | EP1685107A1 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
| 08/02/2006 | EP1684806A1 Compositions and methods of treatment using l-type calcium channel blockers and cholinesterase inhibitors |
| 08/02/2006 | EP1684786A1 Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue |
| 08/02/2006 | EP1684779A1 Method for controlling angiogenesis in animals |
| 08/02/2006 | EP1684772A1 Therapeutic peg solution concentrate |
| 08/02/2006 | EP1684755A1 Use of (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dymethyl-pyridine-3,5-dicarboxylate in the treatment of memory disorders |
| 08/02/2006 | EP1684753A2 Neuromuscular blocking agents and antagonists thereof |
| 08/02/2006 | EP1684745A2 Hepatitis c virus inhibitors |
| 08/02/2006 | EP1684722A2 Medicamentously targeted local lipolysis |
| 08/02/2006 | EP1684712A2 Combination drug therapy to treat obesity |
| 08/02/2006 | EP1684703A2 Methods and compositions for treating mcp-1 related pathologies |
| 08/02/2006 | EP1684690A2 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| 08/02/2006 | EP1532147B1 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 08/02/2006 | EP1505965B1 Use of the metabolite of valsartan to inhibit platelet aggregation |
| 08/02/2006 | EP1492821B1 Iron dextrin compounds for the treatment of iron deficiency anaemia |
| 08/02/2006 | EP1478380B1 Use of tyrosine kinase inhibitors for treating cns disorders |
| 08/02/2006 | EP1435971B1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |